Department of Internal Medicine, Armed Forces Medical College, Pune 411040, Maharashtra, India.
Department of Internal Medicine, Command Hospital, Pune 411040, Maharashtra, India.
World J Gastroenterol. 2021 Oct 21;27(39):6572-6589. doi: 10.3748/wjg.v27.i39.6572.
Pancreatic carcinoma (PC) is one of the leading causes of cancer-related deaths worldwide. Despite early detection and advances in therapeutics, the prognosis remains dismal. The outcome and therapeutic approach are dependent on the stage of PC at the time of diagnosis. The standard of care is surgery, followed by adjuvant chemotherapy. The advent of newer drugs has changed the landscape of adjuvant therapy. Moreover, recent trials have highlighted the role of neoadjuvant therapy and chemoradiotherapy for resectable and borderline resectable PC. As we progress towards a better understanding of tumor biology, genetics, and microenvironment, novel therapeutic strategies and targeted agents are now on the horizon. We have described the current and emerging therapeutic strategies in PC.
胰腺癌(PC)是全球癌症相关死亡的主要原因之一。尽管早期检测和治疗方法有所进步,但预后仍然不佳。PC 的预后和治疗方法取决于诊断时的 PC 分期。标准治疗方法是手术,然后是辅助化疗。新型药物的出现改变了辅助治疗的格局。此外,最近的试验强调了新辅助治疗和放化疗在可切除和边缘可切除 PC 中的作用。随着我们对肿瘤生物学、遗传学和微环境的理解不断深入,新的治疗策略和靶向药物现已初见端倪。我们已经描述了 PC 中当前和新兴的治疗策略。